Abstract: Rapid diagnosis of acute myocardial infarction is critical for intervention and treatment to decrease morbidity and mortality. For this reasons, this study aimed to design a sensitive biosensor for cardiac troponin I (cTnI) for early prediction and intervention. The sensor was designed from golden plate immobilized with anti-cTnI antibody conjugated with horseradish peroxidase (HRP) enzyme. The rate of degradation of H2O2 is directly related to serum cTnI level. Serum cTnI level was quantified from 3 studied groups including; healthy subjects and patients with ischemic heart (IHD) diseases and myocardial infarction (MI) by ELISA and biosensor techniques to achieve the improved sensitivity of the biosensor. It was found that cTnI levels in healthy subjects ranged from 8-13 ng/dl and in patients with IHD ranged from 20 -41 ng/dl and MI range from 57-180 ng/dl. The sensitivity of biosensor was ranged from 85-95% compared with ELISA technique. The developed biosensor is promising in ICU hospitals for early diagnosis and prevent complications of the stroke. It is recommended to apply this biosensor in the large scale of patients with different stages of the cardiac disease. .
Introduction
Coronary heart disease (CHD) happens when lipids accumulates on blood vessels leads to decrease of elasticity of vessels and formation of clots that obstruct the flow of blood to the heart muscle. CHD causes angina pectoris, myocardial infarction, or heart attack. Accurate and exact diagnosis of CHD can help cardiologist for making decision to fast intervene and control the progress of disease leading to better management. Serum cardiac biomarkers can help in early diagnosis and prognosis to differentiate between coronary heart disease and chest pain, of these markers, troponin I, CK-MB2 and myoglobin are the most routine tests used in the hospital. Three types of Troponins (troponin C, troponin T, and troponin I) are found in cardiac muscles that contribute to muscle contraction. The total creatine kinase (CK) activity is a biomarker of myocyte damage in MI and in severe muscle breakdown, dystrophy, autoimmune myositides, and acute kidney injury. Three isoforms of the enzyme CK1 (MM), CK2 (MB) and CK3 (BB) are found predominantly in skeletal, heart and brain muscles. The CK2 has been used as an indication for myocardial damage in CHD. In addition, the sensitivity of serum troponin I level assessment replaces CK2 level in most cases.
Myoglobin is released from the blood into the urine in muscle injuries. The fabrication of activated gold nanoparticles bind to activated substance to obtained monolayer of gold nanoparticle to bind with ligand on their surface [5] . The ligand was used as anti-thyroxin and immobilized with surface plasmon resonance that bind with tracer of thyroxin [6] . Also, amyloid-β derived diffusible ligands (ADDLs), and specific anti-ADDL antibodies was used to be localized in specific optical biosensor to detect the Alzheimer's disease [7] . A golden nanoparticle used to detect specific DNA by using the surface immobilized probe DNA and the metal nanoparticle coated reporter DNA [8] . Eectrocatalytic device containing gold nanoparticles coupled with an electrotrans ducing platform/sensor is achieved to determine the specific identification of tumor cells [9] . The application of gold nanoparticle conjugates in biomedical diagnostics and analytics, photothermal and photodynamic therapies, as a carrier for delivering target molecules, and on the immunological and toxicological properties [10] .
In this study, golden plate immobilized with anti-cTnI antibody conjugated with horseradish peroxidase (HRP) enzyme was designed for early detection of serum cTnI. The designed golden plate biosensor was tested for serum cTnI level in healthy subjects and patients with IHD diseases and myocardial infarction MI with necrosis and compared results with ELISA techniques. The prepared golden plate binding with antibodies may be promising for marketing.
Materials and methods

Preparation of golden plate
Gold nanoparticles with purity 99.99% were used for depositing thin films. The golden nanoparticles (GNP)-Glass substrate was prepared by the pulsed laser deposition (PLD) technique using Neocera Pioneer 180, Neocera, USA. An excimer Laser with KrF gas as a laser source was used [11] . Glass slide was cut to a rectangular shape (1 x 2 cm) and ultrasonicated in ethanol and deionized water for 30 min respectively. After drying slide, it was fixed inside the PLD chamber with a distance of around 10 cm. The chamber was evacuated to a base pressure of 2.2.x10-6 torr. The films were deposited at a laser power of 250 mJ (at 21.2 keV) at room temperature. Around 6000 pulses were used for depositing each film.
To obtain a uniform thickness slide was rotated during the deposition at a speed 50 deg/sec. This deposition was carried out in the vacuum without inserting any other gas. The prepared gold coated on glass biosensors (GCB) was then thoroughly rinsed with water. Then, GCB surface was treated with 20 mM cystamine dihydrochloride for 30 min at room temperature. Cystamine was adsorbed on the exposed patterns of the gold surface and protein (anti-troponin I) binding covalently attached to the amino groups of cystamine. After rinsing with deionized water, 4 % glutaraldehyde solution was treated to the surface of GCB for 30 min at room temperature, to introduce aldehyde residue, which can bind amine residue of the protein surface.
Characterization of prepared golden plate
The morphology and microstructures of the deposited GNP in these films were analyzed with the field emission scanning electron microscopy (SEM) (FESEM, JSM-7500F, JEOL, Japan) and field emission transmission electron microscope (TEM) (FETEM, JEM 2100F, JEOL, Japan). The plates were also analyzed by tapping mode atomic force microscopy (AFM). The thickness of the deposited films was measured by SEM cross-section imaging and using the surface profiler, DEKTAK 150 Veeco, UK.
Preparation of antibody-enzyme conjugates
100 µl of anti-cTn I monoclonal antibody (mAB) (purchased from Meridian Life Science (ME, USA) was completed to 10ml of 25 mM Tris buffer with 0.15 M sodium chloride, pH 7.2. The conjugation between horseradish peroxidase HRP (0.132mg/ml) and anti-troponin mAb was performed by using HRP conjugation kit (Pierce® Conjugate Purification Kit-44920, Thermo Fisher Scientific Inc).
Subjects
Format consent was taken from all subjects before the start of the study.
Eighteen serum samples were collected from cardiology Unit, King Abdul-Aziz Hospital categorized equally into 3 groups: Group I:
Normal, age range 30-55 years, free from any systematic diseases such as diabetic, hypertension, CVD, renal or respiratory. Group II: Male subjects range 32-65 years, suffered from ischemic heart disease.
Group III: Male subjects range 31-70 years, suffered from myocardial infarction.
Measurements of serum cTnI by GCB and ELISA techniques
Serum cTnI level was measured by ELISA technique by using commercial kits purchased from Abcam Company. Antibodies of cTnI are immobilized in the polystyrene well. 50 µl sample or standard (troponin I) and 50 µl of conjugated anti cTnI were added to the wells. After one hour incubation, the wells were washed. 100 µl of Tetramethylbenzidine (TMB) substrate was added and during 10 min incubation is catalyzed by HRP, generating blue coloration. This reaction was then stopped by adding 100 µl Stop Solution The intensity of color was measured at 450 nm.
Serum cTnI level was measured by prepared GCB technique. 100-µl of prepared antibody solution was added at room temperature for 5 min to GCB in Petri dish, washed and blocked with 5% albumin. 100-µl of serum sample was added to the GCB then gently shakes the Petri dish and set at room temperature for 15 min. After washing with Tris-saline buffer, 2 ml of prepared an HRP conjugated anti-troponin mAb was added and shake for two hours. 10 µL of 8 mM H2O2 and 900-µlTris were added and incubated for 15 min, and then 80µL of 40 mM guaiacol was added and read by spectrophotometer at 420 nm [12] .
Results
The three-dimensional microstructure of golden plate biosensors (GPB) was observed by SEM (Fig 1a) and TEM (fig 1b,c) showed uniform thickness film with 94 nm layer with the absence of mesoporosity that indicated high quality, more efficient plate bind with primary antibody of troponin I o on their surface. The results of AFM images illustrated the surface morphology and roughness of gold-coated glass before and after treatment with cystamine and glutaraldehyde (Fig 2 a and b) respectively. The surface roughness of the GNP is the distribution of surface heights. The roughness increased after GNP treated with cystamine and glutaraldehyde. The actual shape of a surface is effective by surface position and surface heights. It is well known that the melting point of the gold nanoparticles decreases rapidly with decreasing particle size. The treatment of the gold nanoparticles by using cystamine and glutaraldehyde form of spherolytic and hummock-like structures in the gold layers that may be connected with an enhanced diffusion of gold particles at elevated temperature and their aggregation into larger structures.
Analysis of serum troponin I from different patients suffered from cardiac diseases and control subjected by GPB were compared with ELISA results. It was found that serum cTnI levels in healthy subjects ranged from 8-13 ng/dl while in patients with IHD ranged from 20-41 ng/dl and MI ranged from 57-180 ng/dl by using two ELISA and GCP techniques. The data obtained from GPB showed high sensitivity and close to results obtained from ELISA Fig (3) .
The storage stability of GPB was investigated at different conditions. The GPB was kept at 4 °C and then tested for detection of serum troponin I in different samples daily for the activity. The results obtained showed that there were no significant changes observed within one week.
Discussion
The early noninvasive sensitive cardiac biomarker is critically important in ICU of hospitals. The routine methodology used is ELISA techniques. However, the one-step biosensors can simplify the whole process with high sensitivity. In the current study, we have designed a simple, sensitive gold plate biosensor (GPB) for detection of serum cTnI in patients with CHD. Meanwhile, the fabrication of GPB was being controlled by the anti-troponin antibody, developing color, conjugation of antibody with HRP. The biosensor was developed by classic methodology [13] . The complex of antibody labeled with the signal generating enzyme was captured by cTnI and reaction between HRP and H2O2 as the indication for plasma cTnI.
The GNPs binding with antibodies and labeled with HRP generates a colored product after time incubation to detect the target molecule qualitatively [14, 15] . The GPB was designed by using the uniform thin layer of golden nanoparticles. Characterization of GPB was performed by using TEM and SEM techniques showed no mesoporosity with sizes ranging from 10-50 nm. The previous study reported that surface morphology of GPB by using pulse laser deposition structures does not depend significantly on times but depending on the size particles [16, 17] .
The GPB was treated with cystamine to get terminal amino groups reacted with the aldehyde groups to yield imine bonds with HRP. Cystamine also has -SH group that GNPs were absorbed onto -SH group. However, the surface of GPB morphology was changed when treated with cystamine and glutaraldehyde [18, 19, 20] .
Antibodies (Ab) are protein receptors for biosensing due to their specificity towards their specific antigen. The specificity between the Ab and antigen interaction has been applied in GPB for clinical diagnosis. Peptides and enzymes are also receptors for GNPs based sensing as they can be functionalized to the surface of GNPs without losing its activity for recognition [21, 22] . We investigated the storage stability of the GCB with mAb-cTI, there were no significant changes in results observed within one week. Herein, we investigated the accuracy of the cTnI biosensor by comparing the results by determining cTnI in human serum and with ELISA. As presented healthy normal and patients with IHD and MI were performed with two different techniques, sensitivity is ranged from 85-95%. The sensitivity of results obtained by GPB was compared with results of ELISA method. It was found that the values of serum CTI were very close to that obtained by ELISA. On the hand, standard troponin tested with GPB showed recovery with 97.5%. The results of serum troponin I obtained from GPB showed high reliability and close to results obtained from ELISA techniques.
Conclusion
The developed biosensor is promising for early diagnosis and fast intervention for management of CHD. This will decrease the mortality of patients with cardiac disease due to late diagnosis.
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